DocGo Inc. — FY2021 Form 10-K Summary
Business context and reporting period. This annual report covers the fiscal year ended December 31, 2021; it is not a standalone fourth-quarter report. DocGo provides medical transportation and mobile healthcare services in the United States and United Kingdom. Mobile Health includes in-home and on-site care, COVID-19 testing, vaccination and event services. On November 5, 2021, the company completed its business combination with Motion Acquisition Corp. and began trading as DocGo (DCGO); the transaction was accounted for as a reverse recapitalization, with Ambulnz treated as the accounting predecessor.
Financial performance and position
| Metric | FY2021 | FY2020 |
|---|---|---|
| Revenue | $318.7 million | $94.1 million |
| Gross profit / margin | $109.7 million / 34.4% | $31.3 million / 33.4% |
| Operating income (loss) | $15.4 million | ($14.8 million) |
| Consolidated net income (loss) | $19.2 million | ($14.8 million) |
| Net income (loss) attributable to DocGo shareholders | $23.7 million | ($14.4 million) |
| Net cash used in operating activities | $1.9 million | $10.7 million |
- Revenue rose 239%. Mobile Health generated $234.4 million (73.6% of revenue), up from $30.9 million; Transportation Services generated $84.3 million (26.4%), up 33% from $63.2 million.
- COVID-19 testing revenue was approximately $110 million in 2021. Transportation trip volume increased 12% to 179,063, and average trip price rose to $342 from $324.
- Cost of revenue was $209.0 million, or 65.6% of revenue, compared with 66.6% in 2020. Inflation, higher wages and overtime, subcontracted labor, fuel, and medical supplies pressured costs. Operating expenses excluding cost of revenue were approximately $94.4 million.
- Segment operating results diverged: Mobile Health reported $41.7 million of operating income, while Transportation Services reported a $26.4 million operating loss.
- Operating cash flow remained negative despite reported profit, principally reflecting a $58.0 million increase in receivables, partly offset by higher payables and accrued liabilities. Investing activities used $8.6 million; financing activities provided $155.2 million, largely from the business combination and PIPE.
- Year-end cash and cash equivalents were $175.5 million; working capital was reported as $198.1 million. Total current assets were $256.0 million and current liabilities $57.9 million.
- Notes payable totaled $1.9 million; finance lease liabilities were $10.1 million and operating lease liabilities $4.4 million. The year-end line-of-credit balance was effectively zero. The company reported a $12 million revolving facility and disclosed a $1 million draw in January 2022.
- The business combination generated approximately $158 million net of transaction costs. A $5.2 million noncash gain from remeasuring warrant liabilities contributed to 2021 earnings. The filing reports $6.4 million warrants outstanding, exercisable at $11.50 per share.
Material changes versus the prior period
- Revenue mix shifted sharply toward Mobile Health, driven in large part by pandemic-related testing and other mobile-health contracts. Transportation revenue recovered, but remained exposed to changes in medical procedures and event activity.
- The company moved from a $14.8 million consolidated net loss in 2020 to $19.2 million net income in 2021; operating results improved from a $14.8 million loss to $15.4 million income.
- Cash increased by $143.1 million to $175.5 million, primarily due to merger-related financing. Receivables also increased substantially alongside rapid growth.
- DocGo completed the business combination, acquired the remaining 20% of its U.K. subsidiary, and reported one 2021 acquisition for a $2.3 million purchase price.
Outlook, commentary, risks and unusual items
- Management said existing cash, expected operating cash flows and available credit were expected to fund operating requirements for at least the next 12 months. The company did not provide numerical revenue or earnings guidance in the supplied filing text.
- Management’s business plan assumes gradual recovery of transportation volumes and continued demand for Mobile Health. It anticipated inflation moderating in 2022 from 2021 levels, while remaining above levels typical of the prior decade; further cost pressure could reduce gross margins.
- COVID-related testing and vaccination work included short-term contracts and may not persist as the pandemic changes. Management cautioned that replacing this revenue may be difficult. The filing also describes pandemic-related disruption to non-emergency transports, events, staffing, supplies and collections.
- Customer concentration is material: two customers accounted for approximately 26% and 24% of 2021 revenue in the risk discussion; a financial-statement note reports approximately 26% and 23%. Government contract revenue was described as 65.1% of 2021 revenue versus 7.3% in 2020. The filing warns that government funding, contracts and projects can be changed or terminated.
- Other key risks include labor and insurance costs, reliance on provider partners, contract renewals, receivable collection and customer concentration, healthcare regulation and reimbursement, privacy and cybersecurity, rapid growth and acquisition integration, and dependence on COVID-related demand.
- The company disclosed a $1.0 million liability for a settlement of class-based claims, subject to court approval. It also received approximately $2.4 million in accelerated Medicare payments in 2020; about $1.7 million had been recouped by year-end 2021, with $975,415 remaining in accrued liabilities.
- Motion had restated historical financial statements and identified material weaknesses relating to warrant and share classification. DocGo reported a remediation plan; management judged disclosure controls effective, but the filing includes no management assessment or auditor attestation of internal control over financial reporting because of transition and emerging-growth-company exemptions. The consolidated financial statement audit opinion was unqualified.
- Legal proceedings are described as arising in the ordinary course; management stated it believed existing defenses were adequate and did not expect the matters to materially affect the financial statements. The company reported no known platform security breach as of the filing date.
Investor verification points
- Assess whether the $110 million of COVID testing revenue and government-contract revenue can be sustained or replaced, and review contract duration and termination terms.
- Reconcile the customer concentration percentages disclosed in different sections and evaluate the exposure to the two largest customers and government projects.
- Track receivables, collections, bad-debt provisions and operating cash flow against reported earnings as the business scales.
- Monitor segment profitability, especially Transportation Services’ operating loss, and the effect of wage, subcontractor, insurance, fuel and supply costs on margins.
- Review the status of Motion’s historical restatements and control remediation, the $1.0 million settlement approval, and subsequent changes in debt, credit-line use and lease obligations.